First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Authors:

Abstract
No abstract available
Funding Information
  • Merck
  • Robertson Foundation
  • National Institutes of Health
  • Congressionally Directed Medical Research Programs (CA 150646)

This publication has 34 references indexed in Scilit: